Cargando…
Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513406/ https://www.ncbi.nlm.nih.gov/pubmed/16871319 http://dx.doi.org/10.1371/journal.pctr.0010014 |
_version_ | 1782128493958529024 |
---|---|
author | Dunyo, Samuel Ord, Rosalynn Hallett, Rachel Jawara, Musa Walraven, Gijs Mesa, Eduardo Coleman, Rosalind Sowe, Maimuna Alexander, Neal Targett, Geoffrey A. T Pinder, Margaret Sutherland, Colin J |
author_facet | Dunyo, Samuel Ord, Rosalynn Hallett, Rachel Jawara, Musa Walraven, Gijs Mesa, Eduardo Coleman, Rosalind Sowe, Maimuna Alexander, Neal Targett, Geoffrey A. T Pinder, Margaret Sutherland, Colin J |
author_sort | Dunyo, Samuel |
collection | PubMed |
description | OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP. DESIGN: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone. SETTING: The study took place in the town of Farafenni and surrounding villages in the Gambia. PARTICIPANTS: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria. INTERVENTIONS: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d. OUTCOME MEASURES: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers. RESULTS: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups. CONCLUSIONS: The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable. |
format | Text |
id | pubmed-1513406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-15134062007-04-12 Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum Dunyo, Samuel Ord, Rosalynn Hallett, Rachel Jawara, Musa Walraven, Gijs Mesa, Eduardo Coleman, Rosalind Sowe, Maimuna Alexander, Neal Targett, Geoffrey A. T Pinder, Margaret Sutherland, Colin J PLoS Clin Trials Research Article OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP. DESIGN: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone. SETTING: The study took place in the town of Farafenni and surrounding villages in the Gambia. PARTICIPANTS: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria. INTERVENTIONS: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d. OUTCOME MEASURES: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers. RESULTS: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups. CONCLUSIONS: The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable. Public Library of Science 2006-07-21 /pmc/articles/PMC1513406/ /pubmed/16871319 http://dx.doi.org/10.1371/journal.pctr.0010014 Text en © 2006 Dunyo et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Dunyo, Samuel Ord, Rosalynn Hallett, Rachel Jawara, Musa Walraven, Gijs Mesa, Eduardo Coleman, Rosalind Sowe, Maimuna Alexander, Neal Targett, Geoffrey A. T Pinder, Margaret Sutherland, Colin J Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum |
title | Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
|
title_full | Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
|
title_fullStr | Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
|
title_full_unstemmed | Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
|
title_short | Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
|
title_sort | randomised trial of chloroquine/sulphadoxine-pyrimethamine in gambian children with malaria: impact against multidrug-resistant p. falciparum |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513406/ https://www.ncbi.nlm.nih.gov/pubmed/16871319 http://dx.doi.org/10.1371/journal.pctr.0010014 |
work_keys_str_mv | AT dunyosamuel randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT ordrosalynn randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT hallettrachel randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT jawaramusa randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT walravengijs randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT mesaeduardo randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT colemanrosalind randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT sowemaimuna randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT alexanderneal randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT targettgeoffreyat randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT pindermargaret randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum AT sutherlandcolinj randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum |